Patent SG-11201909656Y-A (SG)
Title: Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof
Inventor: SORRENTINO ANTONIO
IPC: A61K31/00
Filed: 2018-04-20
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT omit °nolo Him In mourn° ow (10) International Publication Number WO 2018/193084 Al (51) International Patent Classification: A61K 45/06 (2006.01) A61P 35/00 G01N 33/00 (2006.01) A61P 35/02 A61K 31/7064 (2006.01) A61K 31/00 A61K 31/7088 (2006.01) A61K 38/00 A61K 31/713 (2006.01) A61K 38/19 (21) International Application Number: PCT/EP2018/060172 (22) International Filing Date: 20 April 2018 (20.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17167295.9 20 April 2017 (20.04.2017) EP (71) Applicant: IOMX THERAPEUTICS AG [DE/DE]; Fraunhoferstrasse 13, 82152 Martinsried (DE). (72) Inventors: SORRENTINO, Antonio; c/o DKFZ, Im Neuenheimer Feld 280, 69120 Heidelberg (DE). BECK- HOVE, Philipp; Spitalkellerweg 3, 93059 Regensburg (DE). MICHELS, Tillmann; c/o DKFZ, Im Neuen- heimer Feld 280, 69120 Heidelberg (DE). KHANDELW- AL, Nisit; c/o iOmx Therapeutics AG, Fraunhoferstrasse 13, 82152 Martinsried (DE). BOUTROS, Michael; Un- tere Neckarstrasse 76, 67117 Heidelberg (DE). BREINIG, Marco; In den Fensenbaumen 5, 69198 Schriesheim (DE). SENNHENN, Peter; c/o iOmx Therapeutics AG, Fraun- hoferstrasse 13, 82152 Martinsried (DE). MEIER-EW- ERT, Sebastian; c/o iOmx Therapeutics AG, Fraunhofer- strasse 13, 82152 Martinsried (DE). (74) Agent: KUTTENKEULER, David; Boehmert & Boehmert, Pettenkoferstrasse 22, 80336 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (54) Title: INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF (57) : The invention is based on the surprising fmding that SIK3 is associated with resistance against anti-tumour immune responses. In particular, the invention provides methods for treating proliferative diseases using inhibitors of SIK3, especially nucleic acid or small molecule inhibitors of SIK3. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of certain pro-inflammatory signalling pathways, and/or to kill such cells and/or methods for treating proliferative diseases, using a SIK3 inhibitor together with ligands or agonists of such signalling pathways. Other methods provided by the invention include those involving SIK3 inhibitors to enhance or overcome certain side effects associated with treatments that utilise such signalling pathways, as well as diagnostic, prognostic and monitoring methods and kits based on the detection of SIK3 in a sample obtained from a subject, and screening methods useful for identifying or characterising inhibitors of SIK3.